Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service.

Objectives: The importance of clinical outcome prediction models using artificial intelligence (AI) is being emphasized owing to the increasing necessity of developing a clinical decision support system (CDSS) employing AI. Therefore, in this study, we proposed a "Dr. Answer" AI software based on the clinical outcome prediction model for prostate cancer treated with radical prostatectomy.
Methods: The Dr. Answer AI was developed based on a clinical outcome prediction model, with a user-friendly interface. We used 7,128 clinical data of prostate cancer treated with radical prostatectomy from three hospitals. An outcome prediction model was developed to calculate the probability of occurrence of 1) tumor, node, and metastasis (TNM) staging, 2) extracapsular extension, 3) seminal vesicle invasion, and 4) lymph node metastasis. Random forest and k-nearest neighbors algorithms were used, and the proposed system was compared with previous algorithms.
Results: Random forest exhibited good performance for TNM staging (recall value: 76.98%), while k-nearest neighbors exhibited good performance for extracapsular extension, seminal vesicle invasion, and lymph node metastasis (80.24%, 98.67%, and 95.45%, respectively). The Dr. Answer AI software consisted of three primary service structures: 1) patient information, 2) clinical outcome prediction, and outcomes according to the National Comprehensive Cancer Network guideline.
Conclusion: The proposed clinical outcome prediction model could function as an effective CDSS, supporting the decisions of the physicians, while enabling the patients to understand their treatment outcomes. The Dr. Answer AI software for prostate cancer helps the doctors to explain the treatment outcomes to the patients, allowing the patients to be more confident about their treatment plans.
Competing Interests: Chanjung Lee, Sejin Nam, Dongbum Kim are employed by LifeSemantics. LifeSemantics developed the SW and owns full right to use it for commercial purposes as fit by the company. LifeSemantics has agreed to publish this paper in this journal. The authors worked on the project in common. Dongbum Kim is a Non-registered Director and a head of the R&D team of the company. LifeSemantics has granted permission to use all images in this paper. Mi Jung Rho and Jihwan Park are married couples and are part of the Catholic University, co-participating in the project. For the rest of the authors, there are no conflicts of interest to declare. There are no patents, products in development or marketed products associated with this research to declare.